KLRG1 and malignant colon neoplasm: In MC38 colon cancer and B16F10 melanoma models, combination therapy of anti-KLRG1 and anti-PD-1 antibodies inhibited tumor growth and synergistically reduced tumor volume more than treatment with anti-KLRG1 or anti-PD-1 antibody controls alone [8].